Aclaris Therapeutics Inc. (NASDAQ:ACRS) shares saw an uptick in trading volume on Wednesday . 134,342 shares traded hands during trading, an increase of 24% from the previous session’s volume of 108,375 shares.The stock last traded at $24.57 and had previously closed at $24.38.

Several brokerages have issued reports on ACRS. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th. Guggenheim started coverage on Aclaris Therapeutics in a report on Friday, June 10th. They set a “buy” rating and a $35.00 target price for the company. Finally, Jefferies Group lifted their target price on Aclaris Therapeutics from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, August 12th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $31.25.

The stock’s market capitalization is $524.67 million. The firm has a 50 day moving average price of $21.21 and a 200-day moving average price of $19.73.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.01. On average, analysts forecast that Aclaris Therapeutics Inc. will post ($2.61) EPS for the current fiscal year.

In related news, insider Kamil Ali-Jackson sold 3,738 shares of the company’s stock in a transaction on Friday, August 26th. The stock was sold at an average price of $20.35, for a total transaction of $76,068.30. Following the completion of the sale, the insider now owns 20,289 shares in the company, valued at $412,881.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ra Capital Management, Llc sold 525,550 shares of the company’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $24.19, for a total value of $12,713,054.50. The disclosure for this sale can be found here. Corporate insiders own 46.40% of the company’s stock.

Large investors have recently made changes to their positions in the company. Vivo Capital LLC bought a new stake in shares of Aclaris Therapeutics during the first quarter valued at about $79,427,000. Opaleye Management Inc. bought a new stake in shares of Aclaris Therapeutics during the first quarter valued at about $341,000. EAM Investors LLC bought a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $668,000. BlackRock Institutional Trust Company N.A. increased its stake in shares of Aclaris Therapeutics by 24.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 28,286 shares of the company’s stock valued at $536,000 after buying an additional 5,535 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Aclaris Therapeutics by 18.3% in the first quarter. Geode Capital Management LLC now owns 43,246 shares of the company’s stock valued at $819,000 after buying an additional 6,679 shares during the period. Institutional investors and hedge funds own 71.39% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

5 Day Chart for NASDAQ:ACRS

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.